NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 189)
Posted On: 08/24/2022 5:01:11 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Partners with Skincare Leader, Icon and Pioneer
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biopharmaceuticals, nutraceuticals, cosmetics, agrochem and food/beverage industries, has signed a two-year collaborative research and development agreement with Dr. Adrienne Denese, MD, PhD. Creator of the award-winning SkinScience Labs, Denese is a recognized QVC icon, industry Visionary, anti-aging pioneer and founder and president of Dr. Denese SkinScience, one of the most successful, highly rated, and longest-lasting skincare lines in the history of QVC. According to the agreement, PBI and Dr. Denese SkinScience will work together to develop skincare projects to pursue, developing statements of work (“SOW”) with approved budgets, timetables and remuneration formulas for both companies. The two companies will begin by focusing on the potential for PBI’s unique Ultra Shear Technology(TM) (“UST”) nanoemulsification platform to enhance existing and develop new SkinScience skincare products. “From 2019 to 2021, Dr. Denese averaged close to $20 million per year in total sales,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “In 2022, with help from new channel partner Costco, sales are expected to increase significantly. The launch of a new generation of products processed by PBI’s patented UST platform, for the first-time ever in the cosmeceuticals area, is planned for 2023, which we expect to result in a very fulfilling and exciting year for Dr. Denese and her loyal customers — and for PBI. . . . Although final determination of the order of development of these new and enhanced products is yet to be announced, both Dr. Denese SkinScience and PBI understand that these are potential game-changers in an industry whose 2021 global market size was estimated to be over $130 billion. We look at this partnership as an opportunity for multimillion-dollar accretive revenue growth for both companies over the next two years, with the potential to dramatically enhance the growth trajectory and profitability of both Dr. Denese SkinScience and PBI for years to come.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biopharmaceuticals, nutraceuticals, cosmetics, agrochem and food/beverage industries, has signed a two-year collaborative research and development agreement with Dr. Adrienne Denese, MD, PhD. Creator of the award-winning SkinScience Labs, Denese is a recognized QVC icon, industry Visionary, anti-aging pioneer and founder and president of Dr. Denese SkinScience, one of the most successful, highly rated, and longest-lasting skincare lines in the history of QVC. According to the agreement, PBI and Dr. Denese SkinScience will work together to develop skincare projects to pursue, developing statements of work (“SOW”) with approved budgets, timetables and remuneration formulas for both companies. The two companies will begin by focusing on the potential for PBI’s unique Ultra Shear Technology(TM) (“UST”) nanoemulsification platform to enhance existing and develop new SkinScience skincare products. “From 2019 to 2021, Dr. Denese averaged close to $20 million per year in total sales,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “In 2022, with help from new channel partner Costco, sales are expected to increase significantly. The launch of a new generation of products processed by PBI’s patented UST platform, for the first-time ever in the cosmeceuticals area, is planned for 2023, which we expect to result in a very fulfilling and exciting year for Dr. Denese and her loyal customers — and for PBI. . . . Although final determination of the order of development of these new and enhanced products is yet to be announced, both Dr. Denese SkinScience and PBI understand that these are potential game-changers in an industry whose 2021 global market size was estimated to be over $130 billion. We look at this partnership as an opportunity for multimillion-dollar accretive revenue growth for both companies over the next two years, with the potential to dramatically enhance the growth trajectory and profitability of both Dr. Denese SkinScience and PBI for years to come.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼